InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.77%
)
US TECH 100
19,408.75
(
1.26%
)
Dow Jones
38,778.10
(
0.49%
)
Brent Oil
83.85
(
-0.07%
)
Bitcoin
66,164.48
(
-0.48%
)
Post# of 252232
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

masterlongevity

Send PM Follow Ignore
Followers 25
Posts 2597
Boards Moderated 0
Alias Born 01/07/2004

masterlongevity

Re: genisi post# 182910

Friday, 10/17/2014 5:50:49 PM

Friday, October 17, 2014 5:50:49 PM

Post# of 252232
a lot of the late stage AD companies have gotten quiet after the bapi/sola negative storm.


I noticed gantenerumab has finished their phase 3 recruitment in prodromal AD. Results should be available in 2016. That will be the next big trial to read out.

the earliest a new therapy could come to market is 2017.

solanezumab and crenezumab and MK-8931 results will probably be in 207 or 2018.

anyone who already has symptomatic AD will unfortunately not have a chance to be helped with these products, if any of the compunds make it.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up